Positive News SentimentPositive NewsNASDAQ:LIAN LianBio (LIAN) Stock Forecast, Price & News $1.50 0.00 (0.00%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$1.46▼$1.5650-Day Range$1.50▼$2.2352-Week Range$1.07▼$2.90Volume43,980 shsAverage Volume221,621 shsMarket Capitalization$160.76 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media LianBio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside900.0% Upside$15.00 Price TargetShort InterestHealthy0.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.95) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector685th out of 963 stocksPharmaceutical Preparations Industry313th out of 452 stocks 3.5 Analyst's Opinion Consensus RatingLianBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, LianBio has a forecasted upside of 900.0% from its current price of $1.50.Amount of Analyst CoverageLianBio has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.21% of the float of LianBio has been sold short.Short Interest Ratio / Days to CoverLianBio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LianBio has recently increased by 38.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLianBio does not currently pay a dividend.Dividend GrowthLianBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIAN. Previous Next 3.3 News and Social Media Coverage News SentimentLianBio has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for LianBio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LIAN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added LianBio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LianBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.59% of the stock of LianBio is held by insiders.Percentage Held by Institutions74.85% of the stock of LianBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LianBio are expected to decrease in the coming year, from ($0.95) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LianBio is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LianBio is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLianBio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About LianBio (NASDAQ:LIAN) StockLianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Read More LIAN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIAN Stock News HeadlinesSeptember 8, 2023 | finance.yahoo.comWe're Not Very Worried About LianBio's (NASDAQ:LIAN) Cash Burn RateAugust 28, 2023 | finance.yahoo.comLianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA CardiologySeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 14, 2023 | finance.yahoo.comLianBio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | finance.yahoo.comLianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsJuly 29, 2023 | finance.yahoo.comInstitutions own 21% of LianBio (NASDAQ:LIAN) shares but private equity firms control 54% of the companyJuly 27, 2023 | finance.yahoo.comLianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex BlepharitisJuly 18, 2023 | finance.yahoo.comLianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and ThailandSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."July 17, 2023 | finance.yahoo.comLianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023July 12, 2023 | finance.yahoo.comLianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsJune 26, 2023 | finance.yahoo.comLianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in SingaporeJune 12, 2023 | realmoney.thestreet.com2 Stocks I'm Watching in a Market Supported by FOMO and Short SqueezesJune 8, 2023 | finance.yahoo.comLianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisJune 8, 2023 | marketwatch.comADRs End Mostly Lower, Oatly and LianBio Trade ActivelyJune 6, 2023 | finance.yahoo.comLianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in ChinaJune 1, 2023 | finance.yahoo.comLianBio to Participate in Upcoming Investor ConferencesMay 11, 2023 | finance.yahoo.comLianBio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comLianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of ChinaApril 27, 2023 | realmoney.thestreet.comIs This Just an Oversold Bounce? Let's Take What We Can GetApril 27, 2023 | marketwatch.comLianBio Shares Rise 11% After Positive Mavacamtem Trial ResultsApril 27, 2023 | marketwatch.comADRs End Mostly Lower, Dassault Systemes, LianBio Trade ActivelyApril 21, 2023 | marketwatch.comLianBio Gets China Approval for Priority Review of Mavacamten New Drug AppApril 21, 2023 | finance.yahoo.comLianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic CardiomyopathyApril 21, 2023 | finance.yahoo.comLianBio Promotes Pascal Qian to Chief Commercial OfficerMarch 29, 2023 | markets.businessinsider.comRaymond James Sticks to Its Buy Rating for LianBio Sponsored ADR (LIAN)March 27, 2023 | finance.yahoo.comLianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateSee More Headlines Receive LIAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter. Email Address LIAN Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LIAN CUSIPN/A CIK1831283 Webwww.lianbio.com Phone609-486-2308FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.38% Return on Assets-27.40% Debt Debt-to-Equity RatioN/A Current Ratio12.62 Quick Ratio12.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book0.55Miscellaneous Outstanding Shares107,170,000Free Float99,034,000Market Cap$160.76 million OptionableNot Optionable Beta0.59 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Konstantin Poukalov (Age 39)Founder & Exec. Chairman Dr. Yizhe Wang Ph.D. (Age 53)CEO & Director Comp: $1.34MMs. Yi Larson M.B.A. (Age 43)CFO & Treasurer Comp: $1.41MMs. Brianne Jahn (Age 37)Chief Bus. Officer Mr. Jiang Qian (Age 54)Chief Commercial Officer & GM of China Dr. Michael Humphries M.D.Chief Scientific AdvisorMore ExecutivesKey CompetitorsPDS BiotechnologyNASDAQ:PDSBOncolytics BiotechNASDAQ:ONCYEmergent BioSolutionsNYSE:EBSVerrica PharmaceuticalsNASDAQ:VRCAApplied TherapeuticsNASDAQ:APLTView All CompetitorsInstitutional OwnershipBarclays PLCSold 39,972 shares on 9/21/2023Ownership: 0.021%Affinity Asset Advisors LLCBought 150,676 shares on 8/21/2023Ownership: 0.747%Citadel Advisors LLCBought 14,295 shares on 8/15/2023Ownership: 0.118%Stifel Financial CorpSold 5,500 shares on 8/15/2023Ownership: 0.017%Renaissance Technologies LLCBought 12,300 shares on 8/11/2023Ownership: 0.288%View All Institutional Transactions LIAN Stock - Frequently Asked Questions Should I buy or sell LianBio stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIAN shares. View LIAN analyst ratings or view top-rated stocks. What is LianBio's stock price forecast for 2023? 1 analysts have issued 1 year price objectives for LianBio's shares. Their LIAN share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price. View analysts price targets for LIAN or view top-rated stocks among Wall Street analysts. How have LIAN shares performed in 2023? LianBio's stock was trading at $1.64 at the beginning of 2023. Since then, LIAN stock has decreased by 8.5% and is now trading at $1.50. View the best growth stocks for 2023 here. When is LianBio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our LIAN earnings forecast. How were LianBio's earnings last quarter? LianBio (NASDAQ:LIAN) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07. What ETF holds LianBio's stock ? Loncar China Biopharma ETF holds 27,778 shares of LIAN stock, representing 1.31% of its portfolio. When did LianBio IPO? (LIAN) raised $325 million in an initial public offering on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO. What is LianBio's stock symbol? LianBio trades on the NASDAQ under the ticker symbol "LIAN." Who are LianBio's major shareholders? LianBio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.93%), Affinity Asset Advisors LLC (0.75%), Citigroup Inc. (0.66%), Renaissance Technologies LLC (0.29%), Acadian Asset Management LLC (0.13%) and MYDA Advisors LLC (0.13%). View institutional ownership trends. How do I buy shares of LianBio? Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is LianBio's stock price today? One share of LIAN stock can currently be purchased for approximately $1.50. How much money does LianBio make? LianBio (NASDAQ:LIAN) has a market capitalization of $160.76 million. The company earns $-110,290,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. How many employees does LianBio have? The company employs 163 workers across the globe. How can I contact LianBio? The official website for the company is www.lianbio.com. The company can be reached via phone at 609-486-2308 or via email at ir@lianbio.com. This page (NASDAQ:LIAN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.